R&D Tax Incentive
The R&DTI can offset some eligible R&D costs after the relevant activities and expenditure have been incurred and the program requirements are met.
Technical development consumes cash before commercial outcomes are certain. Australian R&D companies can plan around the R&DTI, ordinary business finance, private capital and strategic investment — but each solves a different timing or risk problem.
The R&DTI can offset some eligible R&D costs after the relevant activities and expenditure have been incurred and the program requirements are met.
Commercial finance may bridge a timing gap where the business has sufficient repayment capacity and the provider accepts the risk.
Equity can suit longer-duration R&D where fixed debt service would reduce the runway needed to reach technical or commercial milestones.
Customers, industry participants and aligned investors can sometimes contribute capital, capability, distribution or validation.
Separate grant programs may exist from time to time, but they have their own eligibility, application windows and assessment criteria. Do not describe the R&DTI itself as a grant.
AI and better systems can extend runway by reducing administrative cost and giving management earlier visibility of spend, experiments and milestones.
Strong R&D businesses can explain what is uncertain technically, what has been learned, what milestones remain, how much cash is required, what the capital funds and what changes when those milestones are achieved.
My approach combines AI-enabled R&D evidence capture with operating and capital readiness. Where there is a compelling fit I can also consider selective principal investment or work with aligned funding partners. No investment or finance is guaranteed.
See investment & growth capitalThe Australian Government describes the R&DTI as a tax incentive that offsets some costs of eligible R&D. Eligibility, record keeping and application requirements must be met.
Official R&DTI program →Tell me what you are developing, the next milestone, forecast R&D spend and what additional capital would enable.
Finance changes timing, not R&DTI entitlement. Provider and investor assessment always applies.